Sermorelin

Name: Sermorelin
Brand: LyoPep

Amidated human GHRH(1-29) research reference

Lot-specific · Batch COACAS 86168-78-7RUO

Batch COA

MOQ1 kit (10 vials) per SKU

Supplied formLinear amidated 29-residue peptide (human GHRH N-terminal active fragment)

Lead time7–14 days

Sermorelin — Lot-specific lyophilized research peptide; confirm colour and physical form on the released-lot COA

Sermorelin — Lot-specific lyophilized research peptide; confirm colour and physical form on the released-lot COA · Representative packaging image · verify the ordered lot

Representative packaging image · verify the ordered lot

Decision summary

Key benefits

Defensible research value includes GHRH-receptor pharmacology, pituitary signalling, pulse-response biology, protease susceptibility, analytical differentiation from modified GHRH analogues and historical-label comparison
Older human studies can inform hypothesis generation but do not establish anti-aging, body-composition, exercise, wellness or long-term safety claims for a current RUO lot.

Published research context is presented for literature orientation only. It is not a dosing, treatment or human-use instruction.

Qualification data

Specifications to confirm against the released lot

CAS: 86168-78-7
Formula: C₁₄₉H₂₄₆N₄₄O₄₂S
Molecular weight: 3357.9 g/mol
Appearance: Lot-specific lyophilized research peptide; confirm colour and physical form on the released-lot COA
Purity: Lot-specific chromatographic purity plus quantitative peptide content; confirm terminal form, counterion, water and related peptides separately · target, verify batch COA
Storage: Follow the released-lot label, COA and stability data for the supplied form. Do not transfer refrigeration, reconstitution or in-use instructions from discontinued Geref products or a compounding-pharmacy preparation to a bulk research lot.
MOQ: 1 kit (10 vials) per SKU
Lead time: 7–14 days

PubChem CID 16132413

Qualification matrix

Identity, purity and content are separate release questions.

Identity

Confirm the stated molecule and supplied form. Start with the matching batch COA; request sequence-level evidence only when the buyer's written procedure requires it and availability or a separate scope has been agreed.

Purity

Review RP-HPLC method conditions, wavelength, integration and related-peak handling. A percentage without the method is not enough.

Content

Net peptide content is not the same as gross lyophilized powder weight. Ask which assay supports the stated amount and whether water/counter-ion is addressed.

Stability

Follow the storage condition stated on the batch COA or label from receipt onward.

Research context

What researchers study about Sermorelin

Sermorelin is an amidated 29-residue peptide corresponding to the N-terminal receptor-active region of human growth-hormone-releasing hormone. Specified sermorelin acetate finished products were historically approved under the Geref name and later discontinued; FDA determined that identified presentations were not withdrawn for reasons of safety or effectiveness. That determination does not make present-day bulk sermorelin an approved medicine. Free peptide and acetate descriptions, counterion burden and quantitative peptide content must be reconciled lot-specifically.

Appropriate laboratory contexts include GHRH-receptor binding and signalling, pituitary cell models, pulse-pattern experiments, proteolytic stability, analogue comparison, identity and salt-form methods, and historical regulatory analysis
No current approved clinical indication applies to this bulk RUO material.

Mechanism context

The question the literature is testing

Sermorelin activates the GHRH receptor and downstream cAMP-dependent signalling in appropriate experimental systems. Its unmodified N-terminal sequence is susceptible to proteolysis, producing shorter exposure than engineered analogues in historical studies. Protocol-specific endocrine responses and pharmacokinetic values cannot be converted into a universal bedtime schedule, dose or clinical benefit.

Evidence map

Research routes and exposure context

Evidence tierApproved finished-product context

Research areaGrowth-hormone axis research

Routes reported in sources

SubcutaneousIntravenousIntranasal

Dose / exposure contextProtocol-specific; verify the cited primary source

Routes and exposure contexts summarize cited studies or approved finished-product labels. They are not instructions for administering this RUO material; no customer dose is provided.

Evidence boundaries

Compatibility, limitations and decision context

Not for human or veterinary administration
Historical finished-product experience cannot establish safety for a different bulk material, formulation, route, population or long-term exposure
Endocrine effects, proliferative signalling, impurities, aggregation, contamination and incorrect salt or content assignment are relevant research risks
Sermorelin is explicitly prohibited as a GHRH analogue under the 2026 WADA Prohibited List.

Interactions reported in the literature

No human combination guidance applies
Claims of additive or synergistic use with ipamorelin, CJC-1295, GHRP-2 or other secretagogues were removed because mechanistic plausibility is not a controlled safety or interaction study
Laboratory combination work requires single-agent controls, authenticated materials and protocol-specific endocrine readouts.

Literature context is not a supplier release result or human-use instruction. Follow your institution's approved laboratory risk assessment.

Batch documentation

Sermorelin batch COAs

Laboratory: Manufacturer's QC laboratoryTests: HPLC purity · MS identity · endotoxin · fill amount

2 mg
5 mg
10 mg

Previews are blurred on purpose so the documents cannot be reused; third-party reports show their first page only. Sales sends the clear full version for the product and strength you ask about.

Independent test fails? Full refund.

Representative records, refreshed periodically

Published COAs show recent representative batches and may not be the newest. For a quote or shipment, sales confirms the lot and sends its COA.

Third-party reports, added progressively

Previews of the first page of third-party reports are on our Quality page and on the matching product pages; sales sends the full report on request. You can also send any vial from your order to an independent laboratory of your choice. Unless agreed otherwise in writing, the buyer pays for optional testing.

Help reviewing your COA

Need help reading a batch COA or third-party report? Sales can explain the test items, specifications and how the results relate to the lot under discussion.

On every batch COA: HPLC purity · MS identity · endotoxin · fill amount · Verify LyoPep

Ask for the current packet, not a generic certificate

Require sequence and C-terminal amide confirmation, intact mass, peptide mapping where appropriate, free peptide or acetate and counterion identity, chromatographic purity, quantitative peptide content, related peptides, water, residual solvents, aggregation or particulates where relevant, container integrity and lot-specific stability
Do not rely on CAS alone because commercial acetate identifiers are inconsistent.

Batch COA for the released lotHPLC purity with method contextMS identity resultEndotoxin resultFill amount (measured content per vial)SDS and handling statement

Available fills

Quote the fill and pack configuration you need

Reference SKUFillBase pack

SERM22 mg10 vials

SML55 mg10 vials

SML1010 mg10 vials

Other format

Also available as a nasal spray (US stock)

Black 10 mL nasal spray bottle with a clear cap — 10 mL nasal spray bottle

Besides lyophilized vials, Sermorelin is also supplied as a nasal spray solution, shipped from our US stock.

Strengths: 2 mg
Bottle sizes: 10 mL or 20 mL
Minimum order: 10 bottles per strength and bottle size
Ships from: Our US stock

Capsules · US stock

Also supplied as capsules

Sermorelin is also supplied in capsule bottles, held in our US stock and shipped within the US. Ask our sales team for a quote. For research use only.

Strength: 500 mcg per capsule
Ships from: Our US stock

Handling

Plan storage before the parcel arrives

Follow the released-lot label, COA and stability data for the supplied form. Do not transfer refrigeration, reconstitution or in-use instructions from discontinued Geref products or a compounding-pharmacy preparation to a bulk research lot.

State the destination and timing so receipt can be planned, then move the material into its stated storage condition on arrival.

Buyer FAQ

Terms to settle before the purchase order

Can a buyer arrange third-party testing?+

Yes. You can send any vial from your order to an independent laboratory of your choice. If you want the laboratory, specification, sampling, method and acceptance rule agreed with us before testing, sales confirms them in writing. Unless otherwise agreed in writing, the buyer pays the cost of this optional testing.

What if my own lab test shows the product is out of specification?+

Send any vial from your order to an independent laboratory of your choice. If the report shows the product does not meet the specification on its COA — purity below the stated minimum, or an identity that does not match — share the report with our sales team and we refund that product in full.

Does HPLC purity prove peptide content?+

No. Chromatographic purity describes the relative peak profile under a stated method. Identity, water, counter-ion, residual solvents and assay/content may require separate methods.

How should material be stored after delivery?+

Move it into the storage condition stated on the batch COA or label as soon as it arrives, and record the package condition on receipt.

How are payment terms handled?+

Available methods and milestones depend on order value, destination and project type. The pro forma invoice should state currency, bank details, fees, payment milestones and the release condition.

Why must the testing laboratory understand peptide chemistry?+

Free-base and salt forms, hydrophilic and hydrophobic sequences, aggregation and adsorption can change sample preparation and method suitability. Use a laboratory experienced with the molecule class.

External qualification references

WHO good storage and distribution practices ISO/IEC 17025 laboratory competence 21 CFR 211.84 component testing and supplier COA controls

These are buyer-qualification references, not claims that this RUO material is regulated, certified or released under those frameworks. Applicability depends on the buyer's workflow and jurisdiction.

Selected sources

Literature behind the research context

1) FDA Federal Register notice published March 4, 2013: Geref NDA 019-863 was approved December 28, 1990 and NDA 020-443 on September 26, 1997; discontinuation notices were submitted in 2008, approvals were withdrawn effective June 18, 2009, and FDA determined the named products were not withdrawn for safety or effectiveness reasons. 2) PubChem: free peptide CID 16132413, C₁₄₉H₂₄₆N₄₄O₄₂S, 3357.9 Da; one-acetate CID 16132412, C₁₅₁H₂₅₀N₄₄O₄₄S, 3417.9 Da. 3) The 2026 WADA Prohibited List names sermorelin among prohibited GHRH analogues. 4) Memdouh et al., Drug Test Anal. 2021;13:1871-1887, PMID 34665524, DOI 10.1002/dta.3183: an in-vitro metabolism and UHPLC-MS/MS detection study included sermorelin and a sermorelin(3-29)-NH₂ metabolite, with target-peptide detection limits generally 1 ng/mL or lower. These analytical results do not authorize use of a current RUO lot.

01
Growth hormone (GH)-releasing hormone-(1-29) twice daily reverses the decreased GH and insulin-like growth factor-I levels in old men
Journal of Clinical Endocrinology & Metabolism · 1992 · peer-reviewed original research (randomized dose-comparison trial)
Open source
02
Effects of single nightly injections of growth hormone-releasing hormone (GHRH 1-29) in healthy elderly men
Metabolism: Clinical and Experimental · 1997 · peer-reviewed original research (placebo-controlled trial)
Open source
03
Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency
BioDrugs · 1999 · peer-reviewed narrative review
Open source
04
Sermorelin: a better approach to management of adult-onset growth hormone insufficiency?
Clinical Interventions in Aging · 2006 · peer-reviewed editorial/commentary
Open source
05
Evaluation and Treatment of Adult Growth Hormone Deficiency: An Endocrine Society Clinical Practice Guideline
Journal of Clinical Endocrinology & Metabolism · 2011 · regulatory/professional-society clinical practice guideline
Open source
06
Advances in the detection of growth hormone releasing hormone synthetic analogs
Drug Testing and Analysis · 2021 · peer-reviewed analytical validation study
Open source
07
Determination That GEREF (Sermorelin Acetate) Injection Products Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness
Federal Register (U.S. Government) · 2013 · regulatory document (FDA Federal Register notice)
Open source
08
The 2026 List of Prohibited Substances and Methods
World Anti-Doping Agency · 2026 · official international sport regulation
Open source

Product FAQ

Questions buyers ask about Sermorelin

How should sermorelin be distinguished from CJC-1295 and tesamorelin?+

All engage the GHRH receptor, but they are different chemical entities. Sermorelin is amidated human GHRH(1-29); CJC-1295 variants contain sequence substitutions and may or may not include a DAC group; tesamorelin contains an N-terminal trans-3-hexenoyl modification and is an active ingredient in approved finished drugs. Identity, molecular mass, salt form, evidence and regulatory status cannot be transferred among them.

What does the former Geref approval mean for a current research lot?+

FDA records show that specified Geref sermorelin acetate finished products were discontinued and were not withdrawn for reasons of safety or effectiveness. That historical determination does not approve a new supplier, bulk peptide, concentration, sterile presentation or clinical use. A current RUO lot must be qualified from its own manufacturing and release documents.

What should be checked on a sermorelin batch package?+

Request sequence and C-terminal amide confirmation, intact mass and peptide mapping where appropriate, free-peptide or acetate identity, chromatographic purity, quantitative peptide content, related peptides, counterion, water, residual solvents, aggregation or particulates where relevant, container integrity and lot-specific stability. PubChem lists the free peptide as CID 16132413, C₁₄₉H₂₄₆N₄₄O₄₂S, 3357.9 Da, and the one-acetate record as CID 16132412, C₁₅₁H₂₅₀N₄₄O₄₄S, 3417.9 Da. Endotoxin, bioburden and sterility are separate study-dependent attributes and require separate validated results.

Evidence before order

Buyer intelligence

Ready for review

Request a usable quote

Include fill, quantity, target purity/content, required methods, destination and timing.

B2B response target: 24 hours
1 kit MOQ per SKU
Batch COA: HPLC, MS, endotoxin, fill

Research Use Only. Human-use requests are not accepted.

Recent activity window

Recent confirmed orders including Sermorelin

Recent Confirmed Orders2 · Last 30 days

Australia23 g2026-10-22

Retatrutide 60 mg · Sermorelin 10 mg · Hexarelin Acetate 5 mg · Semaglutide 50 mg · Tesa+IP5 15 mg · BPC-157 10 mg · Melanotan II 10 mg · Kisspeptin-10 10 mg · TB500 Fragment (Frag 17-23) 10 mg · CJC-1295 without DAC 10 mg · MOTS-c (Human) 40 mg

United States25.5 g2026-10-21

GHK-Cu 100 mg · Semaglutide 50 mg · Survodutide 10 mg · Sermorelin 10 mg · Hexarelin Acetate 5 mg · AHK-Cu 100 mg · Bacteriostatic Water 3 ml

Only a portion of all confirmed orders is shown here.

Sermorelin

Key benefits

Specifications to confirm against the released lot

Identity, purity and content are separate release questions.

What researchers study about Sermorelin

The question the literature is testing

Research routes and exposure context

Compatibility, limitations and decision context

Interactions reported in the literature

Sermorelin batch COAs

Ask for the current packet, not a generic certificate

Quote the fill and pack configuration you need

Also available as a nasal spray (US stock)

Also supplied as capsules

Plan storage before the parcel arrives

Terms to settle before the purchase order

Literature behind the research context

Growth hormone (GH)-releasing hormone-(1-29) twice daily reverses the decreased GH and insulin-like growth factor-I levels in old men

Effects of single nightly injections of growth hormone-releasing hormone (GHRH 1-29) in healthy elderly men

Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency

Sermorelin: a better approach to management of adult-onset growth hormone insufficiency?

Evaluation and Treatment of Adult Growth Hormone Deficiency: An Endocrine Society Clinical Practice Guideline

Advances in the detection of growth hormone releasing hormone synthetic analogs

Determination That GEREF (Sermorelin Acetate) Injection Products Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness

The 2026 List of Prohibited Substances and Methods

Questions buyers ask about Sermorelin

Buyer intelligence

Compare adjacent molecules and documentation needs.

CJC-1295 without DAC

Ipamorelin

Tesamorelin

GHRP-2